Unavailable
Unavailable
Save time and jump to the most important pieces.
SC 13D/A - SINOVAC BIOTECH LTD (0001084201) (Subject)
SC 13D/A - SINOVAC BIOTECH LTD (0001084201) (Subject)
SC 13G/A - SINOVAC BIOTECH LTD (0001084201) (Subject)
6-K - SINOVAC BIOTECH LTD (0001084201) (Filer)
6-K - SINOVAC BIOTECH LTD (0001084201) (Filer)
6-K - SINOVAC BIOTECH LTD (0001084201) (Filer)
Sinovac Biotech Ltd. (NASDAQ:SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that its board of directors (the "Board") has appointed Sven H. Borho, CFA, as director to the Board to fill in a vacancy created by a recent resignation. As a qualified audit committee financial expert under Nasdaq Rule 5605, Mr. Borho has also been elected as the Chair of the Audit Committee of the Board. Mr. Borho is a founder and Managing Partner of OrbiMed and has over 30 years of experience investing in the healthcare sector. OrbiMed is a leading healthcare investment firm with approximately $17 billion in assets under management. OrbiMed invests
BOSTON, March 20, 2025 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ:SVA) ("Sinovac") shareholder Heng Ren Partners, LLC funds ("Heng Ren") today sent an open letter to Sinovac's shareholders outlining the significant and decisive action that Sinovac's Board of Directors must take to create liquidity and release cash to shareholders. Specifically, Heng Ren demands that Sinovac's Board of Directors announce a distribution of $8.9 billion in cash to its shareholders and cause the resumption of trading of the Company's shares. The full text of the letter follows: March 20, 2025 Dear Fellow Sinovac Shareholders: Like you, we are shareholders in Sinovac Biotech Ltd. ("Sinovac" or the "Company").
Sinovac Biotech Ltd. (NASDAQ:SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that SINOVAC has received on February 8, 2025 a formal court order (the "Order") from the Privy Council following the previously announced Privy Council Judgment (the "Judgment") which ruled, among others, that (i) the slate of nominees proposed by a group of shareholders at the 2018 Annual General Meeting was rightfully elected to the board of directors of SINOVAC and (ii) the Company's Rights Agreement (also known as poison pill agreement) was invalid. Upon the receipt of the Order, SINOVAC has begun to implement the Judgment and the Order. As the Co
BOSTON, March 20, 2025 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ:SVA) ("Sinovac") shareholder Heng Ren Partners, LLC funds ("Heng Ren") today sent an open letter to Sinovac's shareholders outlining the significant and decisive action that Sinovac's Board of Directors must take to create liquidity and release cash to shareholders. Specifically, Heng Ren demands that Sinovac's Board of Directors announce a distribution of $8.9 billion in cash to its shareholders and cause the resumption of trading of the Company's shares. The full text of the letter follows: March 20, 2025 Dear Fellow Sinovac Shareholders: Like you, we are shareholders in Sinovac Biotech Ltd. ("Sinovac" or the "Company").
Sinovac Biotech Ltd. (NASDAQ:SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, has filed its 2021 annual report on Form 20-F with the U.S. Securities and Exchange Commission for the year ended December 31, 2021. The Company also reported its unaudited financial for the second half and full year ended December 31, 2021. Second Half and Full Year 2021 Financial Summary Sales for the six months ended December 31, 2021 were $8.4 billion, compared to $442.9 million in the prior year period. Sales in 2021 were $19.4 billion, compared to $510.6 million in the prior year. The Company posted $3.4 billion of net income attributable to common sharehol
Sinovac Biotech Ltd. (NASDAQ:SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, announced today its unaudited financial results for the six months ended June 30, 2021. First Half of 2021 Financial Summary Sales for the six months ended June 30, 2021 were $11.0 billion, compared to $67.7 million in the prior year period. The Company posted $5.1 billion of net income attributable to common shareholders, or $51.42 per basic and $44.80 per diluted share, in the six months ended June 30, 2021, compared to net loss attributable to common shareholders of $12.6 million, or $0.13 loss per basic and diluted share, in the prior year period. Mr. Weidon
Sinovac Biotech Ltd. (NASDAQ:SVA) ("Sinovac" or the "Company"), a leading provider of biopharmaceutical products in China, has filed its 2020 annual report on Form 20-F with the U.S. Securities and Exchange Commission for the year ended December 31, 2020. The Company also reported its unaudited financial results for the fourth quarter ended December 31, 2020. Fourth Quarter and Full Year 2020 Financial Summary Sales for the fourth quarter of 2020 were $327.5 million, an increase from $81.1 million in the prior year period. Sales in 2020 were $510.6 million, an increase from $246.1 million in the prior year. Operating income for the fourth quarter increased by 583.7% from the prior